WP IP

News and commentary on IP issues

UK Supreme Court invalidates transgenic mouse patents for insufficiency

Wednesday, 24 June 2020

Katherine Ellis

Patents

Regeneron Pharmaceuticals' European patent EP 1360287 and its divisional EP 2264163 relate to methods of producing transgenic mice able to produce antibodies having human sequences, and the mice produced thereby. These patents covered the idea of producing mice having mixed human-murine gene sequences that could be subsequently modified t...

3613 Hits

Tags:

Regeneron Pharmaceuticals mice sufficiency patent transgenic

3613 Hits

Williams Powell are regulated by IPREG whose code of conduct can be found here.

These pages aim to provide a source of information for both non-professional enquirers e.g. inventors and their companies in the U.K. and professional consultants and advisers throughout the rest of the world. The pages are not intended to provide legal advice, which will only be provided on direct application to us in the formal context of a client/attorney relationship.

The information provided is correct to the best of our knowledge and belief, but is provided without obligation or guarantee. It will be updated from time to time as needed.